BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and ...
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback